The invention concerns paclitaxel solubilizers and formulations thereof with
a high propensity to dissolve paclitaxel. The formulations of the invention reduce
or obviate the need for the disadvantageous excipient Cremophor EL. The formulations
of the invention are useful for administering paclitaxel, its derivatives, or pharmaceutically
acceptable salts or such derivatives to patients in need thereof. The formulations
of the invention are suitable for parenteral, oral, local, or transdermal administration
to mammals including humans, particularly for intravenous delivery.
